Kaly Mueller joined the ALS Therapy Development Institute in 2018 after spending four years at Massachusetts General Hospital, where she researched the potential mechanisms behind neuronal death in Huntington's disease and ALS. As a member of the in vivo team, her current focus is providing detailed and accurate phenotypes for novel mouse models in hopes of incorporating them into future pre-clinical drug studies. She draws inspiration from the strength of ALS patients and their families, as well as the passion her coworkers display on a daily basis. Kaly graduated with a BS in Physiology from Marquette University in 2012, and an MS in Medical Science from Boston University in 2014.